Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind multicenter study of pradefovir mesylate tablets in chronic hepatitis B
CTR20210143Phase 3Active
- Sponsor
- Xi'an Xintong Pharmaceutical
- Start
- Sep 2020
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pradefovir, tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB), sponsored by Xi'an Xintong Pharmaceutical. Started Sep 2020; status: active.
02
Drugs
pradefovirtenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20210143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210143.